Abstract
This study aims to evaluate the efficacy of gabapentin treatment in dry eye disease (DED) and neuropathic ocular pain. Our study was performed with 72 patients. The painDETECT questionnaire was used for neuropathic pain screening. Patients who were thought to have severe DED according to ocular surface disease index (OSDI) questionnaire, Schirmer’s test type 1 and tear break up time test results were treated with artificial tear and cyclosporine drops. Gabapentin treatment was also initiated in addition to artificial tear and cyclosporine drops treatments to the patients with neuropathic component and DED findings. We divided the patients into two groups: group 1 (n: 36), patients treated with artificial tear and cyclosporine drops and group 2 (n: 36), patients treated with artificial tear, cyclosporine drops and gabapentin. In the first evaluation, no significant differences were found between groups in terms of OSDI score, Schirmer’s test result and TBUT. After the 6 weeks of treatment, in both groups OSDI score, Schirmer’s test result and TBUT statistically significantly improved. OSDI score, Schirmer’s test result and TBUT significantly improved after the 6 weeks of gabapentin treatment than artificial tear and cyclosporine treatment group (p < 0.001). Dry eye patients should be screened for neuropathic ocular pain symptoms and individualized treatment has to be applied. Our study showed that the use of gabapentin is effective in severe dry eye patients with neuropathic ocular pain.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
The epidemiology of dry eye disease (2007) Report of the epidemiology subcommittee of the international dry eye workshop. Ocul Surf 5:93–107
Galor A, Feuer W, Lee DJ, Florez H, Venincasa VD, Perez VL (2013) Ocular surface parameters in older male veterans. Investig Ophthalmol Vis Sci 54:1426–1433
Guthoff RF, Wienss H, Hahnel C, Wree A (2005) Epithelial innervation of human cornea: a three-dimensional study using confocal laser scanning fluorescence microscopy. Cornea 24:608–613
Belmonte C, Acosta MC, Merayo-Lloves J et al (2015) What causes eye pain? Curr Ophthalmol Rep 3:111–121
Kalangara JP, Galor A, Levitt RC, Felix ER, Alegret R, Sarantopoulos CD (2016) Burning eye syndrome: do neuropathic pain mechanisms underlie chronic dry eye? Pain Med 17(4):746–755
Galor A, Levitt RC, Felix ER, Martin ER, Sarantopoulos CD (2015) Neuropathic ocular pain: an important yet underevaluated feature of dry eye. Eye (Lond) 29(3):301–312
Goyal S, Hamrah P (2016) Understanding neuropathic corneal pain—gaps and current therapeutic approaches. Semin Ophthalmol 31(1–2):59–70
Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P (2006) EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13:1153–1169
Lichtinger A, Purcell TL, Schanzlin DJ, Chayet AS (2011) Gabapentin for postoperative pain after photorefractive keratectomy: a prospective, randomized, double-blind, placebo-controlled trial. J Refract Surg 27(8):613–617
Alkan H, Ardıc F, Erdogan C, Sahin F, Sarsan A, Findikoglu G (2013) Turkish Version of the painDETECT Questionnaire in the assessment of neuropathic pain: a validity and reliability study. Pain Med 14:1933–1943
Irkec MT, Turkish OSDI Study Group (2007) Reliability and validity of turkish translation of the ocular surface disease index (OSDI) in dry eye syndrome. Investig Ophthalmol Vis Sci 48(13):408
Jensen TS, Baron R, Haanpaa M et al (2011) A new definition of neuropathic pain. Pain 152(10):2204–2205
Galor A, Zlotcavitch L, Walter SD et al (2015) Dry eye symptom severity and persistence are associated with symptoms of neuropathic pain. Br J Ophthalmol 99(5):665–668
Chao C, Golebiowski B, Stapleton F (2014) The role of corneal innervation in LASIK-induced neuropathic dry eye. Ocul Surf 12(1):32–45
Spierer O, Felix ER, McClellan AL et al (2016) Corneal mechanical thresholds negatively associate with dry eye and ocular pain symptoms. Investig Ophthalmol Vis Sci 57(2):617–625
Vehof J, Kozareva D, Hysi PG et al (2013) Relationship between dry eye symptoms and pain sensitivity. JAMA Ophthalmol 131(10):1304–1308
Crane AM, Levitt RC, Felix ER, Sarantopoulos KD, McClellan AL, Galor A (2017) Patients with more severe symptoms of neuropathic ocular pain report more frequent and severe chronic overlapping pain conditions and psychiatric disease. Br J Ophthalmol 101(2):227–231
McMonnies CW (2017) The potential role of neuropathic mechanisms in dry eye syndromes. J Optom 10(1):5–13
Crane AM, Feuer W, Felix ER, Levitt RC, McClellan AL, Sarantopoulos KD, Galor A (2017) Evidence of central sensitisation in those with dry eye symptoms and neuropathic-like ocular pain complaints: incomplete response to topical anaesthesia and generalised heightened sensitivity to evoked pain. Br J Ophthalmol 101(9):1238–1243
McGreevy K, Bottros MM, Raja SN (2011) Preventing chronic pain following acute pain: risk factors, preventive strategies, and their efficacy. Eur J Pain Suppl 5:365–372
Zollner C, Mousa S, Klinger A, Förster M, Schäfer M (2008) Topical fentanyl in a randomized, double-blind study in patients with corneal damage. Clin J Pain 24(8):690–696
Wenk HN, Nannenga MN, Honda CN (2003) Effect of morphine sulphate eye drops on hyperalgesia in the rat cornea. Pain 105(3):455–465
Acknowledgements
We thank all patients for participating in this study.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval
This study was approved by Pamukkale University Medical School Non-Interventional Clinical Trials Ethics Committee.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ongun, N., Ongun, G.T. Is gabapentin effective in dry eye disease and neuropathic ocular pain?. Acta Neurol Belg 121, 397–401 (2021). https://doi.org/10.1007/s13760-019-01156-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13760-019-01156-w